A J Scheen

422 total citations
22 papers, 351 citations indexed

About

A J Scheen is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Pharmacology. According to data from OpenAlex, A J Scheen has authored 22 papers receiving a total of 351 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Endocrinology, Diabetes and Metabolism, 4 papers in Molecular Biology and 4 papers in Pharmacology. Recurrent topics in A J Scheen's work include Diabetes Treatment and Management (8 papers), Pharmacology and Obesity Treatment (4 papers) and Diabetes Management and Research (4 papers). A J Scheen is often cited by papers focused on Diabetes Treatment and Management (8 papers), Pharmacology and Obesity Treatment (4 papers) and Diabetes Management and Research (4 papers). A J Scheen collaborates with scholars based in Belgium and France. A J Scheen's co-authors include Philippe Lefèbvre, Pierre Lefebvre, Manuel J. Castillo, Bernard Jandrain, Delphine Magis, Luc F. Van Gaal, Nicolas Paquot, Patrick Emonts, Frank Nobels and Axelle Pintiaux and has published in prestigious journals such as Diabetes Care, Cardiovascular Diabetology and Annales d Endocrinologie.

In The Last Decade

A J Scheen

21 papers receiving 333 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A J Scheen Belgium	7	179	150	86	60	58	22	351
Kiyofumi Honda Japan	7	194 1.1×	176 1.2×	112 1.3×	39 0.7×	29 0.5×	10	324
A J Scheen Belgium	9	166 0.9×	107 0.7×	79 0.9×	49 0.8×	30 0.5×	23	368
C. H. L. Shackleton United States	10	352 2.0×	148 1.0×	65 0.8×	64 1.1×	42 0.7×	14	585
Abdolkarim Mahrooz Iran	15	113 0.6×	154 1.0×	63 0.7×	42 0.7×	28 0.5×	35	449
Simona Stan Canada	9	86 0.5×	175 1.2×	99 1.2×	59 1.0×	32 0.6×	11	415
Peili Wu China	10	91 0.5×	130 0.9×	47 0.5×	49 0.8×	23 0.4×	27	390
R R Henry United States	6	129 0.7×	217 1.4×	78 0.9×	76 1.3×	28 0.5×	8	398
Lucy S. Jun United States	6	87 0.5×	154 1.0×	88 1.0×	42 0.7×	62 1.1×	6	358
Mark S. Borja United States	14	197 1.1×	151 1.0×	145 1.7×	47 0.8×	44 0.8×	18	469
Taro Okamoto Japan	12	215 1.2×	121 0.8×	143 1.7×	33 0.6×	45 0.8×	32	438

Countries citing papers authored by A J Scheen

Since Specialization

Citations

This map shows the geographic impact of A J Scheen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A J Scheen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A J Scheen more than expected).

Fields of papers citing papers by A J Scheen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A J Scheen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A J Scheen. The network helps show where A J Scheen may publish in the future.

Co-authorship network of co-authors of A J Scheen

This figure shows the co-authorship network connecting the top 25 collaborators of A J Scheen. A scholar is included among the top collaborators of A J Scheen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A J Scheen. A J Scheen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Scheen, A J. (2025). Obesity and global warming: A two-way relationship?. Annales d Endocrinologie. 86(3). 101783–101783.

Velho, Gilberto, Pierre‐Jean Saulnier, Louis Potier, et al.. (2022). Differential prognostic burden of cardiovascular disease and lower-limb amputation on the risk of all-cause death in people with long-standing type 1 diabetes. Cardiovascular Diabetology. 21(1). 71–71. 2 indexed citations

Emonts, Patrick, et al.. (2013). [Management of gestational diabetes].. PubMed. 68(9). 489–96. 4 indexed citations

Scheen, A J & Luc F. Van Gaal. (2013). [Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation].. PubMed. 68(10). 504–10. 1 indexed citations

Scheen, A J. (2013). [How I treat ... with metformin a diabetic patient with moderate renal insufficiency].. PubMed. 68(4). 190–5. 1 indexed citations

Scheen, A J & Luc F. Van Gaal. (2012). [Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination].. PubMed. 67(2). 91–7. 2 indexed citations

Scheen, A J. (2007). [ADOPT study: which first-line glucose-lowering oral medication in type 2 diabetes?].. PubMed. 62(1). 48–52. 6 indexed citations

Scheen, A J. (2006). [The IDEAL study comparing simvastatin 20-40 mg versus atorvastatin 80 mg for secondary prevention after myocardial infarction: between two ideas of the ideal].. PubMed. 61(1). 53–9. 4 indexed citations

Radermecker, Régis, et al.. (2006). [Effects of glimepiride (Amarylle) in type 2 diabetic patients: results of the Belgian study RECORD in general medicine].. PubMed. 61(5-6). 423–9. 1 indexed citations

10.

Scheen, A J. (2005). [Similar reduction in new cases of type 2 diabetes with angiotensin receptor blocker and ACE inhibitor: comparison of meta-analyses of prospective randomised trials].. PubMed. 60(5-6). 424–8. 2 indexed citations

11.

Nobels, Frank, et al.. (2005). [Initiave to promote quality of care and epidemiology of diabetes mellitus].. PubMed. 60(5-6). 624–7. 2 indexed citations

12.

Gaal, Luc F. Van, et al.. (2005). [The cost of type 2 diabetes: summary of the Cost of Diabetes in Europe-Type II study (CODE-2) and analysis of the situation in Belgium].. PubMed. 60(5-6). 278–84. 7 indexed citations

13.

Magis, Delphine, Bernard Jandrain, & A J Scheen. (2004). [Alcohol, insulin sensitivity and diabetes].. PubMed. 58(7-8). 501–7. 18 indexed citations

14.

Paquot, Nicolas, et al.. (2003). [Adiponectin: a new adipocytokine].. PubMed. 58(9). 554–8. 2 indexed citations

15.

Scheen, A J. (2003). [Medication of the month. Glucovance in type 2 diabetes, a fixed combination of metformin-glibenclamide for the treatment of a bipolar metabolic disease].. PubMed. 58(6). 448–52. 2 indexed citations

16.

Scheen, A J, et al.. (2002). [How I explore ... the risk of a patient developing type 2 diabetes].. PubMed. 57(2). 113–5. 4 indexed citations

17.

Scheen, A J. (2001). Thiazolidinediones and liver toxicity.. PubMed. 27(3). 305–13. 132 indexed citations

18.

Scheen, A J, Nicolas Paquot, & Pierre Lefebvre. (1999). [Glucotoxicity and lipotoxicity, two implicated accomplices in the vicious circle of type 2 diabetes].. PubMed. 54(6). 535–8. 3 indexed citations

19.

Scheen, A J. (1999). [Clinical study of the month. The CAPPP study: "The Captopril Prevention Project"].. PubMed. 54(3). 197–9. 7 indexed citations

20.

Scheen, A J, Manuel J. Castillo, & Pierre Lefebvre. (1996). Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications.. PubMed. 22(6). 397–406. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact